KIR2DL1 and acute myeloid leukemia: Since the KIR2DL1/HLA-C*04 genotype seems to favor the escape of leukemic clones refractory to conventional and NK cell therapies (HSCT), these children should be candidates for alternative treatments such as BiTe, CART, or experimental treatment for AML.